Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study

Laura Vertechy; Serena Maria Boccia; Giordana Tiberi; Giacomo Avesani; Giacomo Corrado; Anna Fagotti; Giovanni Scambia; Claudia Marchetti

doi:10.1136/ijgc-2022-003764

Article info

other Versions

You are currently viewing an earlier version of this article (February 06, 2023).
View the most recent version of this article

Original research

Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study

Authors

Laura Vertechy Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Serena Maria Boccia Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Giordana Tiberi Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Giacomo Avesani Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Giacomo Corrado Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles
Anna Fagotti Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyCatholic University of Sacred Heart, Rome, Italy PubMed articles Google scholar articles
Giovanni Scambia Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyCatholic University of Sacred Heart, Rome, Italy PubMed articles Google scholar articles
Claudia Marchetti Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy PubMed articles Google scholar articles

Correspondence to Professor Giovanni Scambia, Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma 00168, Italy; giovanni.scambia{at}policlinicogemelli.it

View Full Text

Citation

Vertechy L, Boccia SM, Tiberi G, et al

Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case–control study

International Journal of Gynecologic Cancer Published Online First: 23 December 2022. doi: 10.1136/ijgc-2022-003764

Publication history

Received July 25, 2022
Accepted November 23, 2022
First published December 23, 2022.

Article Versions

You are currently viewing a Previous version of this article (6 February 2023).
View the most recent version of this article

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

other Versions

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

other Versions

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password